Chemring stock analysis
Want to see GB:BC88 full AI Analyst Report?
Chemring (BC88) Share Price & Analysis
BC88 Stock Chart & Stats
- Day’s Range
- GBX 95.00 - GBX 97.00
- 52-Week Range
- GBX 95.00 - GBX 97.00
- Previous Close
- GBX 108.00
- Volume
- N/A
- Average Volume (3M)
- 1,762
- Market Cap
- GBP 1.37B
- Enterprise Value
- GBP 1488.06T
- Total Cash (Recent Filing)
- GBP 44.70M
- Total Debt (Recent Filing)
- GBP 189.20M
- Price to Earnings (P/E)
- 0.0
- Beta
- N/A
- Next Earnings
- Dec 08, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 02, 2026
- Dividend Yield
- 0.00%
Bulls Say, Bears Say
Bulls Say
Improved Profitability
Improved net, EBIT, and EBITDA margins indicate stronger operating leverage and better profitability in the latest year. If maintained, this can increase internally generated earnings, support investment in defence capabilities, and strengthen resilience across future contract cycles.
Positive Operating Cash Flow
Positive operating cash flow shows that Chemring’s core activities are generating cash despite weaker free cash flow. Continued operating cash generation provides a foundation for funding operations, meeting obligations, and supporting strategic investment over the medium term.
Contracted Defence Demand
Exposure to government and prime-contractor customers, alongside multi-year procurement programs and framework agreements, can provide greater revenue visibility than purely transactional markets. Chemring’s Countermeasures and Sensors & Information segments also diversify its defence applications.
Bears Say
Revenue Decline And Volatility
The latest revenue contraction and history of earnings volatility weaken confidence that recent profitability improvements will be consistent. Uneven demand across defence procurement cycles can make planning, resource allocation, and sustained margin performance more difficult over the next several quarters.
Negative Free Cash Flow
Negative free cash flow means operating cash did not cover investment and/or working-capital requirements in the latest year. If this persists, Chemring may have less flexibility to fund growth internally and could face greater reliance on balance-sheet resources.
Rising Debt Load
The sharp increase in debt raises financial risk even though overall debt-to-equity remained moderate at about 0.40. Higher leverage can reduce flexibility if growth or cash generation softens, while increasing the importance of disciplined capital allocation.
Chemring News
BC88 FAQ
What was Chemring’s price range in the past 12 months?
What is Chemring’s market cap?
When is Chemring’s upcoming earnings report date?
Is Chemring overvalued?
Does Chemring pay dividends?
What is Chemring’s EPS estimate?
How many shares outstanding does Chemring have?
Which hedge fund is a major shareholder of Chemring?
What is the TipRanks Smart Score and how is it calculated?
Chemring Stock Smart Score
Company Description
Chemring
Chemring Group PLC is a prominent company specializing in defense technology, structured around two core operational segments. The first, Sensors and Information, is responsible for designing and manufacturing electronic countermeasures, alongside systems for detecting chemical and biological threats, and equipment for explosive hazard detection (EHD). The second and primary revenue-generating segment, Countermeasures and Energetics, focuses on the development and production of expendable countermeasures for both aerial and naval platforms, cartridge and propellant-activated devices, pyrotechnic solutions for satellite launch and deployment, missile components, propellants, separation sub-systems, actuators, and a variety of energetic materials. Geographically, the United Kingdom accounts for the majority of the company's revenue.
- Sector
- Industrials
- Industry
- Aerospace & Defense
- CEO
- Michael Ord
- Employees
- 2,786
- Website
- www.chemring.co.uk
- Address
- Roke Manor, Romsey, SO51 0ZN, GB
Chemring (BC88) Earnings & Revenues
BC88 Earnings Call
Earnings Call SentimentPositive
The call presented a largely positive operational and financial picture: record order intake and order book, modest revenue growth, expanding margins, exceptional cash conversion and strong Energetics and countermeasures performance underpin medium-term growth. Notable near-term challenges include Roke's decline driven by UK budget timing, a material CapEx increase in Norway (partially grant-funded), higher near-term capital spend and lower cash conversion guidance for FY '26, and some underperforming legacy assets being divested. On balance, the strategic wins, strong balance sheet, and execution evidence outweigh the short-term timing and cost pressures.
View all GB:BC88 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 12 | 3 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 0 | 12 | 0 |







